EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

BACKGROUND: The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), and subsequent treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Anne C., Fernandes, Ancilla W., Pavilack, Melissa, Wu, Jennifer W., Laliberté, François, Duh, Mei Sheng, Chehab, Nabil, Subramanian, Janakiraman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189688/
https://www.ncbi.nlm.nih.gov/pubmed/32345265
http://dx.doi.org/10.1186/s12885-020-06826-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189688/
https://www.ncbi.nlm.nih.gov/pubmed/32345265
http://dx.doi.org/10.1186/s12885-020-06826-0

Ejemplares similares